Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AQST
STRONG SELLAquestive Therapeutics, Inc. · Healthcare · United States · $462M · Avg Vol: $8M/d
COMPANY DESCRIPTION
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing film-based drug delivery products, primarily for unmet medical needs in central nervous system (CNS) disorders. Its proprietary PharmFilm® technology enables convenient, rapid-onset, and non-invasive administration of medications. This specialized drug delivery platform provides a distinct advantage in developing differentiated therapeutic options.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 47.7M | 50.6M | 57.6M | 44.5M | -2.2% | 50.3M | 50.5M | 71.9M | 27.1% |
| EPS | -1.85 | -0.49 | -0.13 | -0.51 | -0.78 | — | -0.58 | -0.42 | -0.45 | — |
| Shares | — | 125.5M | 68.5M | 91.4M | 122.0M | -2.7% | 125.5M | — | — | — |
| Debt | — | 57.5M | 33.3M | 38.0M | 42.5M | -9.6% | 43.6M | — | — | — |
| Equity | — | -118.6M | -106.5M | -60.2M | -33.7M | — | — | — | — | — |
| Op CF | — | -9.8M | -6.4M | -35.8M | -52.4M | — | -43.8M | — | — | — |
| Inv CF | — | -2.5M | -1.0M | -0.2M | -0.6M | — | — | — | — | — |
| Fin CF | — | 11.6M | 4.0M | 83.6M | 102.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AQST are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AQST | Aquestive Therapeutics, Inc.(you) | $462M | 18 | STRONG SELL |
| VREO.CN | Vireo Growth Inc. | $500M | 36 | HOLD |
| AKBA | Akebia Therapeutics, Inc. | $327M | 33 | SELL |
| EOLS | Evolus, Inc. | $394M | 39 | HOLD |
| LFCR | Lifecore Biomedical, Inc. | $162M | 13 | STRONG SELL |
| ESPR | Esperion Therapeutics, Inc. | $817M | 33 | SELL |
| DERM | Journey Medical Corporation | $170M | 25 | SELL |
| BIOA | BioAge Labs, Inc. | $968M | 31 | SELL |
| ORGO | Organogenesis Holdings Inc. | $308M | 39 | HOLD |
| TKNO | Alpha Teknova, Inc. | $266M | 36 | HOLD |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%